TLR4 and influenza: Dong and colleagues (91) have developed a novel influenza vaccine formulation consisting of virosomes with the Toll-like receptor 4 (TLR4) ligand monophosphoryl lipid A (MPLA) and the metal-ion-chelating lipid DOGS-NTA-Ni incorporated into the membrane.